Vienna (Austria), April 20, 2007 – H.M. Pharma Consultancy continues to develop its focus on predictive preclinical and early-stage clinical drug development strategies. Following well-attended and much-acclaimed presentations at Cambridge Health Institute’s Molecular Medicine Tri-Conference in San Francisco in February, followed IBC’s Discovery to IND Conference in Baltimore in March, the next such event will take place at CHI’s World Pharmaceutical Congress, to be held at the Pennsylvania Conference Center, Philadelphia on June 12-13, 2007.

The presentation, held by H.M. Pharma Consultancy’s founder and principal, Dr. Hermann Mucke, will address microdosing in preclinical development. This approach can extract an unprecedented amount of functionally relevant information from a low number of experimental animals.

This is another element in H.M. Pharma Consultancy’s strategic focus on advising drug developers on technologies that can accelerate and streamline the drug development process. Several strategic reports and market overviews focusing on this approach are available from our publishing partner, Insight Pharma Reports (www.insightpharmareports.com; formerly CHI Advances Reports).